生存数据-话题@MedSci

#生存数据#

13篇内容 | 1155人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1688485, encodeId=33f816884854b, content=<a href='/topic/show?id=90c56900065' target=_blank style='color:#2F92EE;'>#生存数据#</a>, objectTitle=IMpower010研究生存数据首次公布，夯实阿替利珠单抗为标准辅助治疗方案！| WCLC 2022速递, objectType=article, longId=735782, objectId=d1d6e3578230, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d1d6e3578230, replyNumber=0, likeNumber=97, createdTime=2023-04-17, rootId=0, userName=thinkibmz_44722603, userId=a23928597735, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d1d6e3578230, moduleTitle=IMpower010研究生存数据首次公布，夯实阿替利珠单抗为标准辅助治疗方案！| WCLC 2022速递, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d1d6e3578230)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688484, encodeId=dcc6168848414, content=<a href='/topic/show?id=90c56900065' target=_blank style='color:#2F92EE;'>#生存数据#</a>, objectTitle=晚期NSCLC免疫疗法联合化疗 (IO-CT) 耐药的二线治疗怎么选？生存数据比较来了！丨WCLC 2022速递, objectType=article, longId=735771, objectId=6107e357712b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6107e357712b, replyNumber=0, likeNumber=87, createdTime=2023-05-18, rootId=0, userName=thinkibmz_44722603, userId=a23928597735, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6107e357712b, moduleTitle=晚期NSCLC免疫疗法联合化疗 (IO-CT) 耐药的二线治疗怎么选？生存数据比较来了！丨WCLC 2022速递, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6107e357712b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688482, encodeId=45c416884822c, content=<a href='/topic/show?id=90c56900065' target=_blank style='color:#2F92EE;'>#生存数据#</a>, objectTitle=NEJM：Dabrafenib联合Trametinib 治疗III期黑色素瘤患者长期生存数据喜人, objectType=article, longId=200218, objectId=b6bb200218dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6bb200218dc, replyNumber=0, likeNumber=98, createdTime=2020-10-04, rootId=0, userName=thinkibmz_44722603, userId=a23928597735, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6bb200218dc, moduleTitle=NEJM：Dabrafenib联合Trametinib 治疗III期黑色素瘤患者长期生存数据喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6bb200218dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688483, encodeId=a8be1688483dd, content=<a href='/topic/show?id=90c56900065' target=_blank style='color:#2F92EE;'>#生存数据#</a>, objectTitle=免疫治疗头颈部鳞癌一线长生存数据公布, objectType=article, longId=201492, objectId=9afb20149296, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9afb20149296, replyNumber=0, likeNumber=72, createdTime=2021-07-16, rootId=0, userName=thinkibmz_44722603, userId=a23928597735, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9afb20149296, moduleTitle=免疫治疗头颈部鳞癌一线长生存数据公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9afb20149296)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688481, encodeId=28ab1688481df, content=<a href='/topic/show?id=90c56900065' target=_blank style='color:#2F92EE;'>#生存数据#</a>, objectTitle=MacroGenics宣布HER2单抗Margetuximab在转移性乳腺癌患者中的III期临床SOPHIA的第二次总体中期生存数据, objectType=article, longId=181811, objectId=3a1a18181105, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a1a18181105, replyNumber=0, likeNumber=88, createdTime=2020-06-06, rootId=0, userName=thinkibmz_44722603, userId=a23928597735, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a1a18181105, moduleTitle=MacroGenics宣布HER2单抗Margetuximab在转移性乳腺癌患者中的III期临床SOPHIA的第二次总体中期生存数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a1a18181105)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688478, encodeId=1b2716884e844, content=<a href='/topic/show?id=90c56900065' target=_blank style='color:#2F92EE;'>#生存数据#</a>, objectTitle=K 药治疗肺癌的 5 年生存数据出炉, objectType=article, longId=167997, objectId=8e6b16e9975d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e6b16e9975d, replyNumber=0, likeNumber=73, createdTime=2020-02-04, rootId=0, userName=thinkibmz_44722603, userId=a23928597735, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e6b16e9975d, moduleTitle=K 药治疗肺癌的 5 年生存数据出炉, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e6b16e9975d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688479, encodeId=0d2016884e9fd, content=<a href='/topic/show?id=90c56900065' target=_blank style='color:#2F92EE;'>#生存数据#</a>, objectTitle=2019 EHA：Amgen双特异性抗体Blincyto治疗白血病的五年生存数据喜人, objectType=article, longId=168697, objectId=cf5816869ebe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf5816869ebe, replyNumber=0, likeNumber=78, createdTime=2019-06-29, rootId=0, userName=thinkibmz_44722603, userId=a23928597735, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf5816869ebe, moduleTitle=2019 EHA：Amgen双特异性抗体Blincyto治疗白血病的五年生存数据喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf5816869ebe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688480, encodeId=27f01688480d3, content=<a href='/topic/show?id=90c56900065' target=_blank style='color:#2F92EE;'>#生存数据#</a>, objectTitle=临床生存数据新视角:竞争风险模型, objectType=article, longId=180014, objectId=d167180014b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d167180014b1, replyNumber=0, likeNumber=84, createdTime=2020-03-07, rootId=0, userName=thinkibmz_44722603, userId=a23928597735, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d167180014b1, moduleTitle=临床生存数据新视角:竞争风险模型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d167180014b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688477, encodeId=ff1016884e7fc, content=<a href='/topic/show?id=90c56900065' target=_blank style='color:#2F92EE;'>#生存数据#</a>, objectTitle=刘健教授：五年生存数据最接近发达国家水平，乳腺癌诊治进入慢病管理新时代, objectType=article, longId=144226, objectId=f4791442264b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4791442264b, replyNumber=0, likeNumber=97, createdTime=2018-11-03, rootId=0, userName=thinkibmz_44722603, userId=a23928597735, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4791442264b, moduleTitle=刘健教授：五年生存数据最接近发达国家水平，乳腺癌诊治进入慢病管理新时代, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f4791442264b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688476, encodeId=fe6216884e667, content=<a href='/topic/show?id=90c56900065' target=_blank style='color:#2F92EE;'>#生存数据#</a>, objectTitle=Ann Oncol：在全球很大的前瞻性研究中，EGFR突变型患者的临床分子特征和生存数据如何？, objectType=article, longId=107780, objectId=6b6b10e7801a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b6b10e7801a, replyNumber=0, likeNumber=73, createdTime=2018-05-23, rootId=0, userName=thinkibmz_44722603, userId=a23928597735, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b6b10e7801a, moduleTitle=Ann Oncol：在全球很大的前瞻性研究中，EGFR突变型患者的临床分子特征和生存数据如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b6b10e7801a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688474, encodeId=779f16884e41b, content=<a href='/topic/show?id=90c56900065' target=_blank style='color:#2F92EE;'>#生存数据#</a>, objectTitle=Heart：当代先天性心脏病成年人生存数据, objectType=article, longId=59268, objectId=f588592687d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f588592687d, replyNumber=0, likeNumber=68, createdTime=2016-03-28, rootId=0, userName=thinkibmz_44722603, userId=a23928597735, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f588592687d, moduleTitle=Heart：当代先天性心脏病成年人生存数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f588592687d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688475, encodeId=3b1e16884e567, content=<a href='/topic/show?id=90c56900065' target=_blank style='color:#2F92EE;'>#生存数据#</a>, objectTitle=2016 美国肿瘤治疗与生存数据再次更新, objectType=article, longId=70569, objectId=e473e05694e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e473e05694e, replyNumber=0, likeNumber=74, createdTime=2016-08-08, rootId=0, userName=thinkibmz_44722603, userId=a23928597735, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e473e05694e, moduleTitle=2016 美国肿瘤治疗与生存数据再次更新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e473e05694e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688473, encodeId=c0ab16884e374, content=<a href='/topic/show?id=90c56900065' target=_blank style='color:#2F92EE;'>#生存数据#</a>, objectTitle=全新全球癌症生存数据报告, objectType=article, longId=48992, objectId=85804899214, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85804899214, replyNumber=0, likeNumber=58, createdTime=2015-05-03, rootId=0, userName=thinkibmz_44722603, userId=a23928597735, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85804899214, moduleTitle=全新全球癌症生存数据报告, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85804899214)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

生存数据

2020-05-29

thinkibmz_44722603 (审核中...)

前往app查看评论内容

#生存数据#

IMpower010研究生存数据首次公布，夯实阿替利珠单抗为标准辅助治疗方案！| WCLC 2022速递

2023-04-17

thinkibmz_44722603 (审核中...)

前往app查看评论内容

#生存数据#

晚期NSCLC免疫疗法联合化疗 (IO-CT) 耐药的二线治疗怎么选？生存数据比较来了！丨WCLC 2022速递

2023-05-18

thinkibmz_44722603 (审核中...)

前往app查看评论内容

#生存数据#

NEJM：Dabrafenib联合Trametinib 治疗III期黑色素瘤患者长期生存数据喜人

2020-10-04

thinkibmz_44722603 (审核中...)

前往app查看评论内容

#生存数据#

免疫治疗头颈部鳞癌一线长生存数据公布

2021-07-16

thinkibmz_44722603 (审核中...)

前往app查看评论内容

#生存数据#

MacroGenics宣布HER2单抗Margetuximab在转移性乳腺癌患者中的III期临床SOPHIA的第二次总体中期生存数据

2020-06-06

thinkibmz_44722603 (审核中...)

前往app查看评论内容

#生存数据#

K 药治疗肺癌的 5 年生存数据出炉

2020-02-04

thinkibmz_44722603 (审核中...)

前往app查看评论内容

#生存数据#

2019 EHA：Amgen双特异性抗体Blincyto治疗白血病的五年生存数据喜人

2019-06-29

thinkibmz_44722603 (审核中...)

前往app查看评论内容

#生存数据#

临床生存数据新视角:竞争风险模型

2020-03-07

thinkibmz_44722603 (审核中...)

前往app查看评论内容

#生存数据#

刘健教授：五年生存数据最接近发达国家水平，乳腺癌诊治进入慢病管理新时代

2018-11-03

thinkibmz_44722603 (审核中...)

前往app查看评论内容

#生存数据#

Ann Oncol：在全球很大的前瞻性研究中，EGFR突变型患者的临床分子特征和生存数据如何？

2018-05-23

thinkibmz_44722603 (审核中...)

前往app查看评论内容

#生存数据#

Heart：当代先天性心脏病成年人生存数据

2016-03-28

thinkibmz_44722603 (审核中...)

前往app查看评论内容

#生存数据#

2016 美国肿瘤治疗与生存数据再次更新

2016-08-08

thinkibmz_44722603 (审核中...)

前往app查看评论内容

#生存数据#

全新全球癌症生存数据报告

2015-05-03

科室
- - 订阅+
  - 更多科室
工具
服务